• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies
The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].
Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research

When hormonal treatment is not an option
An integrated analysis of safety data from seven Phase 2/3 double-blind, placebo-controlled trials has been conducted for ospemifene (Senshio ®). Adverse drug reactions are well characterized, benign and not unexpected from a SERM used for the treatment of VVA (i.e. hot flushes, leg cramps). There is no evidence to date that ospemifene leads to an increase in vaginal bleeding, endometrial hyperplasia or cancer; VTE, stroke or other cardi ovascular events; or any other adverse event of special interest.
Source: Maturitas - February 14, 2018 Category: Primary Care Authors: Felix Lugo Source Type: research